Results 221 to 230 of about 9,662,184 (369)
Counting the Cost: The Hidden Financial Realities of Neuromuscular Disease Through Patient and Family Perspectives. [PDF]
Osman H +13 more
europepmc +1 more source
A scalable human iPSC-based neuromuscular disease model on suspended biobased elastomer nanofiber scaffolds. [PDF]
Cheesbrough A +5 more
europepmc +1 more source
Contribution of neuromuscular Impairment to physical functional Status in Patients with Lumbar Spinal Stenosis [PDF]
Fossel, Anne H. +4 more
core
Modelling Neuromuscular Diseases in the Age of Precision Medicine [PDF]
Alfina A. Speciale +3 more
openalex +1 more source
Objective Biomarkers with clear contexts of use are important tools for amyotrophic lateral sclerosis (ALS) therapy development. Understanding their longitudinal trajectory in the untreated state is key to their use as potential markers of pharmacodynamic response.
Oleksandr Dergai +16 more
wiley +1 more source
Profiling the TRPV4 ankyrin repeat domain interactome and its disruption by neuromuscular disease-causing mutations. [PDF]
Loder AK +10 more
europepmc +1 more source
Decrease of Muscle Mass in Young Patients With Neuromuscular Disease: Assessment of Sarcopenia. [PDF]
Kim J +6 more
europepmc +1 more source
Respiratory Implications of Pediatric Neuromuscular Disease
H. Panitch
semanticscholar +1 more source
Objective We aimed to evaluate the clinical utility of serum neurofilament light chain (sNfL) and cardiac troponin T (cTnT) in amyotrophic lateral sclerosis (ALS) and assess whether their combination improves diagnostic accuracy. Methods We retrospectively analyzed 293 ALS patients, 85 neurodegenerative disease controls, and 29 healthy controls.
Paula Lindenborn +6 more
wiley +1 more source

